Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5186-5193

  Stoffels, Karolien ^a   Mathys, Vanessa ^a   Fauville Dufaux, Maryse ^a   Wintjens, René ^b   Bifania, Pablo ^a,c  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; PYRAZINAMIDASE; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); GENE MUTATION; GENETIC POLYMORPHISM; IN VITRO STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; CRYSTALLOGRAPHY, X-RAY; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 84866322174     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05385-11     Document Type: Article

References (68)

1. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA. 1995. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39:1700-1703.
2. Ando H, et al. 2010. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin. Microbiol. Infect. 16:1164-1168.
3. Bamaga M, Zhang H, Wright DJ. 2001. New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist. 7:223-228. (Pubitemid 33104596)
4. Barco P, et al. 2006. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J. Antimicrob. Chemother. 58:930-935.
5. Bifani PJ, et al. 1996. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 275:452-457. (Pubitemid 26065618)
6. Boshoff HI, Mizrahi V, Barry CE, 3rd. 2002. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol. 184:2167-2172. (Pubitemid 34259666)
7. Brown TJ, Tansel O, French GL. 2000. Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J. Med. Microbiol. 49:651-656. (Pubitemid 30447280)
8. Butler WR, Kilburn JO. 1983. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob. Agents Chemother. 24:600-601. (Pubitemid 13021442)
9. Campbell PJ, et al. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041.
10. Canetti G, et al. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. World Health Organ. 29:565-578.
11. Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44:528-532. (Pubitemid 30117936)
12. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE, 3rd. 2000. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 97:9677-9682. (Pubitemid 30650835)
13. Dehouck Y, et al. 2009. Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0. Bioinformatics 25:2537-2543.
14. Denkin S, Volokhov D, Chizhikov V, Zhang Y. 2005. Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J. Med. Microbiol. 54:1127-1131. (Pubitemid 41783818)
15. Dessau FI, Yeager RL, Burger FJ, Williams JH. 1952. Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig. Am. Rev. Tuberc. 65:519-522.
16. Dormandy J, et al. 2007. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 131:497-501. (Pubitemid 46280411)
17. Doustdar F, Khosravi AD, Farnia P. 2009. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microb. Drug Resist. 15:251-256.
18. Escalante P, et al. 1998. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber. Lung Dis. 79:111-118. (Pubitemid 29078280)
19. Gangadharam PR. 1986. Murine models for mycobacterioses. Semin. Respir. Infect. 1:250-261.
20. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 78:117-122. (Pubitemid 28080549)
21. Hou L, et al. 2000. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol. Infect. 124:227-232. (Pubitemid 30224130)
22. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. 2010. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 10:223.
23. Jureen P, Werngren J, Toro JC, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:1852-1854. (Pubitemid 351614686)
24. Kocagoz T, et al. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774. (Pubitemid 26277791)
25. Konno K, Feldmann FM, McDermott W. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
26. Kraulis PJ. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:946-950.
27. Kushner S, et al. 1948. Experimental chemotherapy of tuberculosis; substituted nicotinamides. J. Org. Chem. 13:834-836.
28. Kushner S, et al. 1952. Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J. Am. Chem. Soc. 74:3617-3621.
29. Lee KW, Lee JM, Jung KS. 2001. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J. Korean Med. Sci. 16:537-543. (Pubitemid 33741658)
30. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V. 1999. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother. 43:1761-1763. (Pubitemid 29331263)
31. Louw GE, et al. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807. (Pubitemid 44031396)
32. Luria SE, Delbruck M. 1943. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491-511.
33. Malone L, et al. 1952. The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice. Am. Rev. Tuberc. 65:511-518.
34. Marttila HJ, et al. 1999. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob. Agents Chemother. 43:1764-1766. (Pubitemid 29331264)
35. Mathys V, et al. 2009. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53:2100-2109.
36. McDermott DW, et al. 1954. Pyrazinamide-isoniazid in tuberculosis. Am. Rev. Tuberc. 69:319-333.
37. Merritt EA, Murphy ME. 1994. Raster3D, version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr. D 50:869-873. (Pubitemid 2161308)
38. Mestdagh M, et al. 1999. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:2317-2319. (Pubitemid 29421225)
39. Miyagi C, Yamane N, Yogesh B, Ano H, Takashima T. 2004. Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn. Microbiol. Infect. Dis. 48:111-116. (Pubitemid 38221506)
40. Morlock GP, Plikaytis BB, Crawford JT. 2000. Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. Antimicrob. Agents Chemother. 44:3298-3301. (Pubitemid 33009486)
41. Mphahlele M, et al. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459-3464.
42. O'Sullivan DM, McHugh TD, Gillespie SH. 2005. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J. Antimicrob. Chemother. 55:674-679. (Pubitemid 40691845)
43. Park SK, et al. 2001. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect. Dis. 1:4.
44. Parthiban V, Gromiha MM, Schomburg D. 2006. CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res. 34:W239-W242. (Pubitemid 44529771)
45. Perdigao J, et al. 2008. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb. Drug Resist. 14:133-143.
46. Petrella S, et al. 2011. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 6:e15785. doi:10.1371/journal.pone.0015785.
47. Pfyffer GE, et al. 1999. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J. Clin. Microbiol. 37:3179-3186. (Pubitemid 29455202)
48. Portugal I, Barreiro L, Moniz-Pereira J, Brum L. 2004. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 48:2736-2738. (Pubitemid 38823455)
49. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29. (Pubitemid 29050434)
50. Rodrigues Vde F, et al. 2005. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob. Agents Chemother. 49:444-446.
51. Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother. 32:1002-1004.
52. Sandgren A, et al. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:e2. doi:10.1371/journal.pmed.1000002.
53. Scorpio A, et al. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543. (Pubitemid 27098400)
54. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. (Pubitemid 26191953)
55. Sekiguchi J, et al. 2007. Detection of multidrug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 45:179-192. (Pubitemid 46106425)
56. Sheen P, et al. 2009. Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J. Clin. Microbiol. 47:2937-2943.
57. Shi W, et al. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632.
58. Somoskovi A, et al. 2007. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. J. Clin. Microbiol. 45:595-599. (Pubitemid 46277031)
59. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. 1997. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 41:636-640. (Pubitemid 27098417)
60. Stavrum R, Myneedu VP, Arora VK, Ahmed N, Grewal HM. 2009. In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi-predominance of drug resistant isolates of the 'modern' (TbD1) type. PLoS One 4:e4540. doi:10.1371/journal.pone.0004540.
61. Tracevska T, et al. 2004. Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia. Antimicrob. Agents Chemother. 48:3209-3210. (Pubitemid 38989208)
62. Yeager RL, Munroe WG, Dessau FI. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65:523-546.
63. Zhang H, et al. 2008. Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. FEBS J. 275:753-762.
64. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.
65. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21. (Pubitemid 36427026)
66. Zhang Y, Scorpio A, Nikaido H, Sun Z. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049. (Pubitemid 29164956)
67. Zhou J, et al. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525. (Pubitemid 30651049)
68. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:1043-1047.